Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects.
Year: 2005
Type: letter
Abstract: We read with considerable interest the paper by Sheil et al ( Gut 2004; 53 :694–700) who reported the successful application of the subcutaneous route for probiotic attenuation of colitis.
We agree with the corresponding commentary of Ghosh et al ( Gut 2004; 53 :620–2) regarding the need to study mechanisms underlying probiotic interactions. Recently, we further standardised a method to compare the anti-inflammatory potential of orally administered lactic acid bacteria (LAB) in a murine model of acute 2,4,6, trinitrobenzene sulphonic acid (TNBS) induced colitis.1 This model allowed us to discriminate “protective” strains, showing between 30% and 70% reduction of inflammatory score, from strains which did not significantly attenuate experimental colitis. We could select highly performing strains of Lactobacillus salivarius and Lactobacillus rhamnosus that consistently lowered colitis. In comparison, a strain of Lactobacillus acidophilus , Lactococcus lactis , and Streptococcus gordonii never showed any improvement. For all five strains, we investigated the protective effect of a single intraperitoneal injection of 5×107 live microorganisms, 24 …
Source: PubMed
Authors: B Foligné, C Grangette, B Pot
Language: English
Subfield: Food Science
Domain: Life Sciences
Keywords: probiotics, inflammatory bowel disease, colitis, lactic acid bacteria, TNBS-induced colitis, Lactobacillus salivarius, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactococcus lactis, Streptococcus gordonii, intraperitoneal administration, oral administration, anti-inflammatory activity
Open Access status: green
OpenAlex ID: W2139563813
